TNM Classification of Malignant Tumours. Este artículo no está disponible.TNM Classification of Malignant Tumours

The essential reference on cancer stage returns as a fully revised edition

Describing cancer stage is one of the most important elements of oncological practice. Clinical research and clinical care depend on an accurate assessment of cancer stage and prognostic factors. The TNM Classification of Malignant Tumours serves as the globally recognised standard reference for describing cancer stage and assessing treatment results. Now fully updated to reflect the results of the latest clinical research, it is indispensable for all clinicians, cancer registrars and researchers who work with malignant tumours.

Readers of the ninth edition of TNM Classification of Malignant Tumours will find:

• Updates in many tumour sites including, nasopharynx, HPV associated oropharynx, lung, thymus, mesothelioma, appendix, anal canal, cervix, vulva and prostate carcinoma;
• Revised and updated sections on Essential TNM and paediatric cancer staging;
• New classifications for medulloblastoma, cutaneous lymphoma, parathyroid carcinoma, adrenal medulla and extra-adrenal paraganglia tumours;
• Revised classification of prognostic factors for many malignancies.

TNM Classification of Malignant Tumours is an essential resource for anyone involved in cancer care, research or cancer control.

James Brierley, MBBS, FRCP, FRCPSC, FRCR, is Emeritus Professor of Radiation Oncology, University of Toronto, Canada.

Meredith Giuliani, MBBS, Med, PhD, FRCPC, DRCPSC, is Director at the Cancer Education Princess Margaret Cancer Centre, Canada and Associate Professor at the Department of Radiation Oncology, University of Toronto, Canada.

Brian O'Sullivan MB, BCh, FRCPC, FRCPI, FFRRCSI (Hon) is Professor, Department of Radiation Oncology, Centre Hospitalier de l'Universite (CHUM), Montreal, Canada.

Brian Rous, MB, Bchir, MA, PhD, FRCPath, is a Consultant Histopathologist at Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Elisabeth Van Eycken, MD, is Director of the Belgian Cancer Registry, Brussels, Belgium.